Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.50 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17055348 | 0.82 | MAOB (0.47) | MAOBHIF1AEGLN1 | |
| SCHEMBL2992355 | 0.82 | MAOB (0.49) | MAOBHIF1AMALT1 | |
| SCHEMBL2995950 | 0.82 | MAOB (0.49) | MAOBHIF1AKMT2A | |
| SCHEMBL2996781 | 0.81 | MAOB (0.59) | MAOBHIF1AMALT1 | |
| SCHEMBL2993766 | 0.81 | ALOX15 (0.56) | MAOBHIF1AMALT1NPC1RAB9A | |
| SCHEMBL1674346 | 0.80 | ALDH1A1 (0.63) | MAOBHIF1ARAB9A | |
| SCHEMBL21788549 | 0.79 | MAOB (0.46) | MAOBHIF1AMALT1KMT2ANPC1 | |
| SCHEMBL25337209 | 0.78 | CA12 (0.44) | MAOBHIF1AEGLN1 | |
| SCHEMBL29137453 | 0.78 | KDM4E (0.48) | MAOBHIF1AKMT2ANPC1RAB9A | |
| SCHEMBL7238262 | 0.78 | HCAR3 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | claimed |
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | MAOB 3222/4885HIF1A 2401/4885MALT1 3225/4885 |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | MAOB 3222/4885HIF1A 2401/4885MALT1 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.